Böbrek Kanserlerinde İrreversibl Elektroporasyon
Özet
Böbrek kanserlerinde üroonkoloji alanının en dinamik tedavi yaklaşımlarından biri olarak incelenen İrreversibl Elektroporasyon (IRE), erken evre (T1) küçük böbrek tümörlerinin tedavisinde yenilikçi bir minimal invazif yöntem sunmaktadır. Günümüzde T1a evresindeki tümörler için radyofrekans ablasyon (RFA) ve kriyoablasyon gibi termal teknikler başarıyla uygulansa da, hiler bölge ve toplayıcı sisteme yakın kitlelerde vasküler yapılara zarar verme riski taşırlar. IRE ise koagülasyon nekrozu oluşturmak yerine, yüksek voltajlı elektrik pulsları ile hücre membranında nanoporlar açarak apoptozisi tetikler. Kollajen yapılar ve damarlar lipid içermediği için bu akımdan zarar görmez ve böylece hayati çevre dokular korunur. Literatürdeki çalışmalar, IRE’nin %93 civarında yüksek onkolojik başarı sunduğunu ve serum kreatinin ile GFR gibi böbrek fonksiyonlarını olumsuz etkilemediğini göstermektedir. Yöntemin majör komplikasyon riski düşük olup, perirenal hematom, ağrı ve hematüri gibi minör yan etkiler rapor edilmiştir. Ancak işlemin genel anestezi, tam nöromusküler blokaj ve yakın EKG takibi gerektirmesi, ayrıca operasyon süresinin nispeten uzun olması önemli kısıtlamalardır. Sonuç olarak IRE, özellikle santral ve hiler yerleşimli tümörler için güvenilir bir alternatif vadetmekle birlikte, rutin klinik kullanım için daha geniş serili prospektif çalışmalara ihtiyaç duymaktadır.
Examined as one of the most dynamic therapeutic approaches in uro-oncology for renal cancers, Irreversible Electroporation (IRE) offers an innovative, minimally invasive method for treating early-stage (T1) small renal masses. Although thermal ablation techniques such as radiofrequency ablation (RFA) and cryoablation achieve high oncological success for T1a tumors, they pose significant risks to vascular structures and the collecting system when tumors are located near the hilum. Unlike thermal methods, IRE delivers high-voltage electric pulses to create nanopores in cell membranes, inducing apoptosis without causing coagulation necrosis. Since blood vessels and collagen structures lack lipid content, they remain unaffected, thereby preserving critical surrounding tissues. Recent literature demonstrates that IRE provides a high oncological success rate of approximately 93% while successfully preserving renal functions such as serum creatinine and GFR. Reported complications are mostly minor, including perirenal hematoma, transient pain, and hematuria. However, the requirement for general anesthesia, complete neuromuscular blockade, continuous ECG monitoring to prevent arrhythmias, and relatively long procedural times remain notable limitations. In conclusion, while IRE offers a promising alternative for central and hilar renal tumors, extensive prospective trials with larger patient cohorts are required before it can be adopted into routine clinical practice.
Referanslar
T.M. Wah. Image-guided ablation of renal cell carcinoma. Clinical Radiology. 2017;72:636-44.
Remzi M, Marberger M. Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur Urol. 2009;55(2):359e67.
Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol 2008;180(2):505e8.
Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913e24.
Tanagho YS, Bhayani SB, Kim EH, et al. Renal cryoablation versus robotassisted partial nephrectomy: Washington University long-term experience. J Endourol 2013;27:1477 e86.
Govindarajan Narayanan, Mehul H. Doshi Irreversible Electroporation (IRE) in Renal Tumors. Curr Urol Rep. 2016;17(2):15.
Davalos RV,Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223–31.
Edd JF, Davalos RV. Mathematical modeling of irreversible electroporation for treatment planning. Technol Cancer Res Treat. 2007;6(4):275-86.
Yarmush ML, Golberg A, Serša G, Kotnik T, Miklavčič D. Electroporationbased technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng. 2014;16(1):295–320.
Ringel-Scaia VM, Beitel-White N, Lorenzo MF, et al. High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity. EBioMedicine. 2019;44:112–25.
Gissel H, Lee RC, Gehl J. Electroporation and Cellular Physiology. In: Kee ST, Gehl J, Lee EW, eds. Clinical Aspects of Electroporation. New York,NY: Springer, 2011; 9–17.
Wah TM. Image-guided ablation of renal cell carcinoma. Clin Radiol. 2017;72:636-44.
Al-Sakere B, André F, Bernat C, et al. Tumor ablation with irreversible electroporation. PLoS One. 2007;2:e1135.
Faroja M, Ahmed M, Appelbaum L, et al. Irreversible electroporation ablation: is all the damage nonthermal? Radiology 2013;266(2):462–470.
Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48
Wendler JJ et al. Angiography in the isolated perfused kidney: radiological evaluation of vascular protection in tissue ablation by nonthermal irreversible electroporation. Cardiovasc Intervent Radiol. 2012;35(2):383–90.
Tracy CR, Kabbani W, Cadeddu JA. Irreversible electroporation (IRE): a novel method for renal tissue ablation. BJU Int. 2011;107(12):1982–7.
Wendler JJ et al. Urinary tract effects after multifocal nonthermal irreversible electroporation of the kidney: acute and chronic monitoring by magnetic resonance imaging, intravenous urography and urinary cytology. Cardiovasc Intervent Radiol. 2012;35(4):921–6.
Wendler JJ et al. Short- and mid-term effects of irreversible electroporation on normal renal tissue: an animal model. Cardiovasc Intervent Radiol. 2013;36(2):512–20
Pech M et al. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Intervent Radiol. 2011;34(1):132–8.
Thomson KR et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611–21.
J. Savic, J. Chapiro, B. Hamm, B. Gebauer, F. Irreversible Electroporation in Interventional Oncology: WhereWe Stand and WhereWe Go Irreversible Elektroporation: Übersicht und Ausblick. L. Collettini Fortschr Röntgenstr. 2016;188:735–45.
Wendler JJ, Ricke J, Pech M et al. First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial. Cardiovasc Intervent Radiol. 2016;39(2):239-50.
Mara Buijs, Patricia J. Zondervan, Daniel M.de Bruin, Krijn P. van Lienden, et al. Feasibility and safety of irreversible electroporation (IRE) in patients with small renal masses: Results of a prospective study. Seminars and Original İnvestigations 37(2019):183:e1-8)
Noah E. Canvasser, Igor Sorokin, Aaron H. Lay, Monica S. C. Morgan, Asim Ozayar, Clayton Trimmer, Jeffrey A. Cadeddu Irreversible electroporation of small renal masses: suboptimal oncologic efficacy in an early series.. World J Urol. 2017;35:1549–55.
Ziyin Wang, Jian Lu, Wei Huang, Zhiyuan Wu, Ju Gong, Qingbing Wang et al. A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety. BMC Cancer. 2021; 21:124.
